Streetbeat News

Revenues

SOFI

SoFi Technologies forecasts Q1 adjusted net revenue of $550M-$560M, below the estimated $573.87M. The company also expects a 20% adjusted EBITDA margin, $110M-$120M in adjusted EBITDA, and GAAP net income of $10M-$20M for Q1.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 12:09 pm

ARLP

Alliance Resource Partners, L.P. (ARLP) anticipates strong coal sales volumes for FY24, ranging between 34.0M and 35.8M short tons. CEO Mr. Craft expects another record year of revenues, citing over 90% of coal sales volumes already committed and priced at levels similar to 2023. The company has secured premium pricing through multi-year contracts with domestic customers, reflecting the high value placed on their coal quality and reliability.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 12:07 pm

VSTM

Verastem Oncology (NASDAQ:VSTM) has announced its strategic priorities for 2024, focusing on the advancement of its clinical programs for RAS pathway-driven cancers. The company is dedicated to developing new cancer treatments and has highlighted upcoming catalysts for its drugs Avutometinib and Defactinib, as well as its broader pipeline.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 12:04 pm

ABNB

Airbnb (NASDAQ:ABNB) has been reviewed by 13 analysts in the last three months, showing a mix of ratings from bullish to bearish. The average 12-month price target is $131.62, down from the previous $137.20. Analysts have adjusted their ratings and price targets, with some maintaining and others raising or lowering their stance. Airbnb's financial performance shows strong revenue growth, net margin, ROE, and ROA, with prudent debt management. The company's market cap indicates a strong market position.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 12:01 pm

ZIM

Five financial analysts have recently updated their ratings on ZIM Integrated Shipping (NYSE:ZIM), with a mix of bullish, indifferent, and bearish sentiments. The average 12-month price target is now $9.94, down from $10.28, with a high estimate of $20.00 and a low of $5.00. Analysts from Jefferies, B of A Securities, Barclays, and JP Morgan have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. ZIM's financials show a significant revenue decline, poor net margin, low ROE and ROA, and a high debt-to-equity ratio, suggesting challenges ahead.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 12:00 pm

CCCC

Analysts have mixed views on C4 Therapeutics (NASDAQ:CCCC), with recent ratings ranging from bullish to indifferent. The average 12-month price target is now $8.4, down from $10.00, indicating a 16.0% decrease. Analysts from JP Morgan, Stifel, Morgan Stanley, BMO Capital, and HC Wainwright & Co. have made various adjustments to their ratings and price targets. C4 Therapeutics is a biopharmaceutical company with a market cap above industry averages, a revenue growth rate of 63.93%, and strong profitability indicators like net margin and ROE, but a higher debt-to-equity ratio than the industry average.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 12:00 pm

FLYW

Flywire (NASDAQ:FLYW) has been the subject of diverse analyst ratings over the past three months, with 12 analysts offering varying opinions. The recent trend shows a shift towards a more cautious stance, with several analysts lowering their price targets. The average 12-month price target is now $33.17, down from $37.38. Despite this, Flywire's financial performance remains strong, with notable revenue growth and a solid net margin, although its ROE is below industry averages. The company's market capitalization is smaller compared to industry peers, and it has a conservative financial approach with a debt-to-equity ratio of 0.0.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 12:00 pm

GMAB

Genmab (NASDAQ:GMAB) has received diverse analyst ratings in the last three months, with 5 analysts offering views ranging from bullish to somewhat bearish. The average 12-month price target is $45.8, with a high of $50.00 and a low of $32.00, reflecting a 3.32% increase from the previous average of $44.33. Analyst Raghuram Selvaraju from HC Wainwright & Co. has adjusted his price target and maintained a 'Buy' rating, while Matthew Harrison from Morgan Stanley has lowered his rating to 'Underweight' with a price target of $32.00. Genmab, a biotech company specializing in antibody therapeutics, has shown a revenue growth rate of 16.08% and a high net margin of 44.88%, but its revenue growth lags behind industry peers. The company's financial health is strong, with an ROE of 7.11% and an ROA of 6.33%, and a low debt-to-equity ratio of 0.03.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 12:00 pm

BIOL

Biolase projects its full-year 2024 revenue to be between $52M-$53M, reflecting a 6%-8% increase year-over-year, slightly below the consensus estimate of $53.01M. The company also anticipates improving its loss from operations by 50%-60%.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 11:37 am

BIOL

Biolase, Inc. reported its full-year 2023 interim revenue to be between $48.9M and $49.2M, marking a 1% year-over-year increase, which is in line with the consensus estimate of $49.21M. The company saw a significant adoption of its Waterlase dental laser, with 71% of its U.S. sales coming from new customers. Biolase also reported a 45% sales conversion rate in 2023, attributing success to its Waterlase Trial Program. Additionally, the company achieved a record increase in consumable sales, up by approximately 20% from the previous year.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 11:35 am